title: Temozolomide salvage chemotherapy for recurrent anaplastic oligodendroglioma and oligo-astrocytoma.
abstract: OBJECTIVE
  To evaluate the efficacy of temozolomide (TMZ) chemotherapy for recurrent anaplastic oligodendroglioma (AO) and anaplastic oligoastrocytoma (AOA).
  
  
  METHODS
  A multi-center retrospective trial enrolled seventy-two patients with histologically proven AO/AOA who underwent TMZ chemotherapy for their recurrent tumors from 2006 to 2010. TMZ was administered orally (150 to 200 mg/m(2)/day) for 5 days per 28 days until unacceptable toxicity occurred or tumor progression was observed.
  
  
  RESULTS
  TMZ chemotherapy cycles administered was median 5.3 (range, 1-41). The objective response rate was 24% including 8 cases (11%) of complete response and another 23 patients (32%) were remained as stable disease. Severe side effects (≥grade 3) occurred only in 9 patients (13%). Progression-free survival (PFS) of all patients was a median 8.0 months (95% confidence interval, 6.0-10.0). The time to recurrence of a year or after was a favorable prognostic factor for PFS (p<0.05). Overall survival (OS) was apparently differed by the patient's histology, as AOA patients survived a median OS of 18.0 months while AO patients did not reach median OS at median follow-up of 11.5 months (range 2.7-65 months). Good performance status of Eastern Cooperative Oncology Group 0 and 1 showed prolonged OS (p<0.01).
  
  
  CONCLUSIONS
  For recurrent AO/AOA after surgery followed by radiation therapy, TMZ could be recommended as a salvage therapy at the estimated efficacy equal to procarbazine, lomustine, and vincristine (PCV) chemotherapy at first relapse. For patients previously treated with PCV, TMZ is a favorable therapeutic option as 2nd line salvage chemotherapy with an acceptable toxicity rate.
authors: Registration Group, Korean Society for Neuro-Oncology, Korea.
authors: Ho-Shin
authors: HS
authors: Gwak
authors: Registration Group, Korean Society for Neuro-Oncology, Korea.
authors: Gi Taek
authors: GT
authors: Yee
authors: Registration Group, Korean Society for Neuro-Oncology, Korea.
authors: Chul-Kee
authors: CK
authors: Park
authors: Registration Group, Korean Society for Neuro-Oncology, Korea.
authors: Jin Wook
authors: JW
authors: Kim
authors: Registration Group, Korean Society for Neuro-Oncology, Korea.
authors: Yong-Kil
authors: YK
authors: Hong
authors: Registration Group, Korean Society for Neuro-Oncology, Korea.
authors: Seok-Gu
authors: SG
authors: Kang
authors: Registration Group, Korean Society for Neuro-Oncology, Korea.
authors: Jeong Hoon
authors: JH
authors: Kim
authors: Registration Group, Korean Society for Neuro-Oncology, Korea.
authors: Ho Jun
authors: HJ
authors: Seol
authors: Registration Group, Korean Society for Neuro-Oncology, Korea.
authors: Tae-Young
authors: TY
authors: Jung
authors: Registration Group, Korean Society for Neuro-Oncology, Korea.
authors: Jong Hee
authors: JH
authors: Chang
authors: Registration Group, Korean Society for Neuro-Oncology, Korea.
authors: Heon
authors: H
authors: Yoo
authors: Registration Group, Korean Society for Neuro-Oncology, Korea.
authors: Jeong-Hyun
authors: JH
authors: Hwang
authors: Registration Group, Korean Society for Neuro-Oncology, Korea.
authors: Se-Hyuk
authors: SH
authors: Kim
authors: Registration Group, Korean Society for Neuro-Oncology, Korea.
authors: Bong Jin
authors: BJ
authors: Park
authors: Registration Group, Korean Society for Neuro-Oncology, Korea.
authors: Sun-Chul
authors: SC
authors: Hwang
authors: Registration Group, Korean Society for Neuro-Oncology, Korea.
authors: Min Su
authors: MS
authors: Kim
authors: Registration Group, Korean Society for Neuro-Oncology, Korea.
authors: Seon-Hwan
authors: SH
authors: Kim
authors: Registration Group, Korean Society for Neuro-Oncology, Korea.
authors: Eun-Young
authors: EY
authors: Kim
authors: Registration Group, Korean Society for Neuro-Oncology, Korea.
authors: Ealmaan
authors: E
authors: Kim
authors: Registration Group, Korean Society for Neuro-Oncology, Korea.
authors: Hae Yu
authors: HY
authors: Kim
authors: Registration Group, Korean Society for Neuro-Oncology, Korea.
authors: Young-Cho
authors: YC
authors: Ko
authors: Registration Group, Korean Society for Neuro-Oncology, Korea.
authors: Hwan Jung
authors: HJ
authors: Yun
authors: Registration Group, Korean Society for Neuro-Oncology, Korea.
authors: Ji Hye
authors: JH
authors: Youn
authors: Pharmaceutical Benefit Department, Health Insurance Review and Assessment Service, Korea.
authors: Juyoung
authors: J
authors: Kim
authors: Pharmaceutical Benefit Department, Health Insurance Review and Assessment Service, Korea.
authors: Byeongil
authors: B
authors: Lee
authors: Registration Group, Korean Society for Neuro-Oncology, Korea.
authors: Seung Hoon
authors: SH
authors: Lee
keywords: Anaplastic oligoastrocytoma; Anaplastic oligodendroglioma; Chemotherapy; Recurrence; Temozolomide